

## 6. Literaturverzeichnis

- Agodoa LY, Appel L, Bakris GL et al., the African American Study of Kidney Disease and Hypertension (AASK) Study Group. Effect of ramipril vs. amlodipine on renal outcomes in hypertensive nephrosclerosis: a randomized controlled trial. *JAMA*. 2001 Jun 6;285(21):2719-28.
- Altwegg LA, d'Uscio LV, Barandier C, Cosentino F, Yang Z, Luscher TF. Nebivolol induces NO-mediated relaxations of rat small mesenteric but not of large elastic arteries. *J Cardiovasc Pharmacol*. 2000 Sep;36(3):316-20
- Anderson S, Meyer TW, Rennke HG, Brenner BM. Control of glomerular hypertension limits glomerular injury in rats with reduced renal mass. *J Clin Invest* 1985; 76: 612-9.
- Anderson S, Rennke HG, Brenner BM. Therapeutic advantage of converting enzyme inhibitors in arresting progressive renal disease associated with systemic hypertension in the rat. *J Clin Invest*. 1986 Jun;77(6):1993-2000.
- Anderson S, Brenner BM. Therapeutic implications of converting-enzyme inhibitors in renal disease. *Am J Kidney Dis* 1987; 81-7.
- Anderson S, Brenner BM. Intraglomerular hypertension: implications and drug treatment. *Annu Rev Med* 1988; 39: 243-53.
- Anderson S, Meyer TW, Brenner BM. Dietary protein restriction and the progression of chronic renal insufficiency: a review of the literature. *J Intern Med* 1996; 239: 99-104.
- Ardiles LG, Ehrenfeld P, Quiroz Y, et al. Effect of mycophenolate mofetil on kallikrein expression in the kidney of 5/6 nephrectomized rats. *Kidney Blood Press Res*. 2002;25(5):289-95.
- Areekul S. Reflection coefficients of neutral and sulfate substituted dextran molecules in the isolated perfused rabbit ear. *Acta Soc Med Upsal* 1969; 74: 129-38.
- Arnal JF, Warin L, Michel JB. Determinants of aortic cyclic guanosine monophosphate in hypertension induced by chronic inhibition of nitric oxide synthase. *J Clin Invest*. 1992 Aug;90(2):647-52.
- Bakris GL, Weir MR, Secic M, Campbell B, Weis-McNulty A. Differential effects of calcium antagonist subclasses on markers of nephropathy progression. *Kidney Int*. 2004

*Jun;65(6):1991-2002.*

- Bakris GL, Fonseca V, Katholi RE et al; GEMINI Investigators. Differential effects of beta-blockers on albuminuria in patients with type 2 diabetes. *Hypertension*. 2005 Dec;46(6):1309-15. Epub 2005 Nov 14.
- Barone FC, Campbell WG Jr, Nelson AH, Feuerstein GZ. Carvedilol prevents severe hypertensive cardiomyopathy and remodeling. *J Hypertens*. 1998 Jun;16(6):871-84.
- Baudoin P, Provoost AP, Molenaar JC. Renal function up to 50 years after unilateral nephrectomy in childhood. *Am J Kidney Dis* 1993; 21: 603-11.
- Baylis C, Mitruka B, Deng A. Chronic blockade of nitric oxide synthesis in the rat produces systemic hypertension and glomerular damage. *J Clin Invest*. 1992 Jul;90(1):278-81
- Baylis C, Qiu C. Importance of nitric oxide in the control of renal hemodynamics. *Kidney Int*. 1996 Jun;49(6):1727-31
- Bayliss LE, Tookey-Kerridge M, Russell DS. The excretion of protein by the mammalian kidney. *J Physiol* 1933; 77: 386-98.
- Bjorck S, Mulec H, Johnsen SA, Nyberg G, Aurell M. Contrasting effects of enalapril and metoprolol on proteinuria in diabetic nephropathy. *BMJ*. 1990 Apr 7;300(6729):904-7.
- Blaustein MP, Hamlyn JM. Pathogenesis of essential hypertension. A link between dietary salt and high blood pressure. *Hypertension*. 1991 Nov;18(5 Suppl):III184-95.
- Böger RH. Asymmetric dimethylarginine, an endogenous inhibitor of nitric oxide synthase, explains the "L-arginine paradox" and acts as a novel cardiovascular risk factor. *J Nutr*. 2004 Oct;134(10 Suppl):2842S-2847S; discussion 2853S.
- Böger RH, Schwedhelm E, Maas R, Quispe-Bravo S, Skamira C. ADMA and oxidative stress may relate to the progression of renal disease: rationale and design of the VIVALDI study. *Vasc Med*. 2005 Jul;10 Suppl 1:S97-102.
- Borsboom H, Smans L, Cramer MJ et al. Long-term blood pressure monitoring and echocardiographic findings in patients with end-stage renal disease: reverse epidemiology explained? *Neth J Med*. 2005 Nov;63(10):399-406.
- Braun-Mendenez E, Fasciolo JC, Lehoir LF, Munoz JM. La sustancia hipertensora de la sangre del rinon isquemado. *Rev Soc Argent Biol* 1939; 15: 401-408
- Braun-Menendez E, Chiodi H. La funcion renal en la rata blanca despues de la nefrectomia unilateral. *Rev Soc Argen Biol* 1947; 23: 21-7.
- Brenner BM, Meyer TW, Hostetter TH. Dietary protein intake and the progressive nature of kidney disease: the role of hemodynamically mediated glomerular injury in the

pathogenesis of progressive glomerular sclerosis in aging, renal ablation, and intrinsic renal disease. *N Engl J Med* 1982; 307: 652-9.

- Brenner BM. Nephron adaptation to renal injury or ablation. *Am J Physiol* 1985; F324-37.
- Brenner BM, Garcia DL, Anderson S. Glomeruli and blood pressure. Less of one, more the other? *Am J Hypertens.* 1988 Oct;1(4 Pt 1):335-47.
- Brenner BM, Mackenzie HS. Nephron mass as a risk factor for progression of renal disease. *Kidney Int* 1997; 502 (suppl): S124-7.
- Brenner BM, Cooper ME, de Zeeuw D et al.; RENAAL Study Investigators. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. *N Engl J Med.* 2001 Sep 20;345(12):861-9.
- Bright R. Tabular view of the morbid appearances in 100 cases connected with albuminous urine. *Guy's Hosp Rep* 1836; 1:380-400
- Brochu E, Lacasse S, Moreau C et al. Endothelin ET(A) receptor blockade prevents the progression of renal failure and hypertension in uraemic rats. *Nephrol Dial Transplant.* 1999 Aug;14(8):1881-8.
- Brooks DP, Solleveld HA, Contino LC. Vasopressin and the pathogenesis of chronic renal failure. *Br J Pharmacol.* 1990 May;100(1):79-8.
- Bruzzi I, Remuzzi G, Benigni A. Endothelin: a mediator of renal disease progression. *J Nephrol* 1997; 10: 179-83.
- Chang RL, Deen WM, Robertson CR, Brenner BM. Permeability of the glomerular capillary wall: III. Restricted transport of polyanions. *Kidney Int* 1975; 8: 212-8.
- Chanutin A, Ferris E. Experimental renal insufficiency produced by partial nephrectomy. *Arch Intern Med* 1932; 49: 767.
- Coresh J, Astor BC, Greene T, Eknoyan G, Levey AS. Prevalence of chronic kidney disease and decreased kidney function in the adult US population: Third National Health and Nutrition Examination Survey. *Am J Kidney Dis.* 2003 Jan;41(1):1-12.
- Cortes P, Zhao X, Riser BL, Narins RG. Regulation of glomerular volume in normal and partially nephrectomized rats. *Am J Physiol* 1996; F356-70.
- Cowley AW Jr, Mattson DL, Lu S, Roman RJ. The renal medulla and hypertension. *Hypertension.* 1995 Apr;25(4 Pt 2):663-73.
- Dagenais NJ, Jamali F. Protective effects of angiotensin II interruption: evidence for antiinflammatory actions. *Pharmacotherapy.* 2005 Sep;25(9):1213-29.
- Dalla Vestra M, Pozza G, Mosca A et al. Effect of lercanidipine compared with ramipril

on albumin excretion rate in hypertensive Type 2 diabetic patients with microalbuminuria: DIAL study (diabete, ipertensione, albuminuria, lercanidipina). *Diabetes Nutr Metab.* 2004 Oct;17(5):259-66.

- de Zeeuw D, Remuzzi G, Parving HH et al. Proteinuria, a target for renoprotection in patients with type 2 diabetic nephropathy: lessons from RENAAL. *Kidney Int.* 2004 Jun;65(6):2309-20.
- Deen WM, Maddox DA, Robertson CR, Brenner BM. Dynamics of glomerular ultrafiltration in the rat. VII. Response to reduced renal mass. *Am J Physiol* 1974; 227: 556-62.
- Deng LY, Thibault G, Schiffrin EL. Effect of hypertension induced by nitric oxide synthase inhibition on structure and function of resistance arteries in the rat. *Clin Exp Hypertens.* 1993 May;15(3):527-37.
- Dessy C, Saliez J, Ghisdal P et al. Endothelial beta3-adrenoreceptors mediate nitric oxide-dependent vasorelaxation of coronary microvessels in response to the third-generation beta-blocker nebivolol. *Circulation.* 2005 Aug 23;112(8):1198-205.
- Douglas JG, Agodoa L. ACE inhibition is effective and renoprotective in hypertensive nephrosclerosis: the African American Study of Kidney Disease and Hypertension (AASK) trial. *Kidney Int Suppl.* 2003 Feb;(83):S74-6.
- Elema JD, Arends A. Focal and segmental glomerular hyalinosis in the rat. *Lab Invest* 1975; 33: 554.
- Fitzgibbon WR, Greene EL, Grewal JS et al. Resistance to remnant nephropathy in the Wistar-Furth rat. *J Am Soc Nephrol.* 1999 Apr;10(4):814-21.
- Flather MD, Shibata MC, Coats AJ, et al., SENIORS Investigators. Randomized trial to determine the effect of nebivolol on mortality and cardiovascular hospital admission in elderly patients with heart failure (SENIORS). *Eur Heart J.* 2005 Feb;26(3):215-25. *Epub* 2005 Jan 9.
- Foster MH, Sant GR, Donohoe JF, Harrington JT. Prolonged survival with a remnant kidney. *Am J Kidney* 1991; 17: 261-5.
- Fujihara CK, De Lourdes Noronha I, Malheiros, Antunes GR, de Oliveira IB, Zatz R. Combined mycophenolate mofetil and losartan therapy arrests established injury in the remnant kidney. *J Am Soc Nephrol.* 2000 Feb;11(2):283-90.
- Gao YS, Nagao T, Bond RA, Janssens WJ, Vanhoutte PM. Nebivolol induces endothelium-dependent relaxations of canine coronary arteries. *J Cardiovasc Pharmacol.*

1991 Jun;17(6):964-9.

- Garcia DL, Rennke HG, Brenner BM, Anderson S. Chronic glucocorticoid therapy amplifies glomerular injury in rats with renal ablation. *J Clin Invest.* 1987 Sep;80(3):867-74.
- GISEN-group. Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy. The GISEN Group (Gruppo Italiano di Studi Epidemiologici in Nefrologia), *Lancet.* 1997 Jun 28;349(9069):1857-63.
- Goldblatt H, Lynch J, Hanzal R, Summerville WN. Studies on experimental hypertension. I. Production of persistent elevation of systolic blood pressure by means of renal ischemia. *J Exp Med* 1934; 59:347
- Granstam SO, Fellstrom B, Lind L. Influences of carvedilol treatment on the effects of acetylcholine on regional haemodynamics in the spontaneously hypertensive rat. *Clin Sci (Lond).* 1998 Sep;95(3):303-9.
- Griffin KA, Picken MM, Bakris GL, Bidani AK. Class differences in the effects of calcium channel blockers in the rat remnant kidney model. *Kidney Int.* 1999 May;55(5):1849-60.
- Gschwend S, Buikema H, Navis G, Henning RH, de Zeeuw D, van Dokkum RP. Endothelial dilatory function predicts individual susceptibility to renal damage in the 5/6 nephrectomized rat. *J Am Soc Nephrol.* 2002 Dec;13(12):2909-15
- Guijarro C, Massy ZA, Kasiske BL. Clinical correlation between renal allograft failure and hyperlipidemia. *Kidney Int* 1995; 48: S-56-9.
- Guyton AC, Coleman TG, Cowley AV Jr, Scheel KW, Manning RD Jr, Norman RA Jr. Arterial pressure regulation. Overriding dominance of the kidneys in long-term regulation and in hypertension. *Am J Med.* 1972 May;52(5):584-94.
- Hausberg M, Kosch M, Harmelink P et al. Sympathetic nerve activity in end-stage renal disease. *Circulation.* 2002 Oct 8;106(15):1974-9.
- Haynes WG, Noon JP, Walker BR, Webb DJ. Inhibition of nitric oxide synthesis increases blood pressure in healthy humans. *J Hypertens.* 1993 Dec;11(12):1375-80.
- Hostetter TH, Olson JL, Rennke HG, Venkatachalam MA, Brenner BM. Hyperfiltration in remnant nephrons: a potentially adverse response to renal ablation. *Am J Physiol* 1981; 241: F85-93.
- Hostetter TH, Meyer TW, Rennke HG, Brenner BM. Chronic effects of dietary protein in the rat with intact and reduced renal mass. *Kidney Int* 1986; 30: 509-17.

- Hoy WE, Wang Z, VanBuynder P, Baker PR, McDonald SM, Mathews JD. The natural history of renal disease in Australian Aborigines. Part 2. Albuminuria predicts natural death and renal failure. *Kidney Int.* 2001 Jul;60(1):249-56.
- Ikeda T, Yuhara M, Gomi T, Ishimitsu T, Uehara Y. Alteration of vascular thromboxane in rats with subtotal renal ablation. *Prostaglandins Leukot Essent Fatty Acids.* 1989 Sep;37(3):157-61
- Imbert MJ, Berjal G, Moss N, De Rouftignac C, Bonvalet JP. Number of nephrons in hypertrophic kidneys after unilateral nephrectomy in young and adult rats. *Pflugers Arch* 1974; 346: 279-90.
- Intengan HD, Schiffrin EL. Disparate effects of carvedilol versus metoprolol treatment of stroke-prone spontaneously hypertensive rats on endothelial function of resistance arteries. *J Cardiovasc Pharmacol.* 2000 May;35(5):763-8.
- Irie F, Iso H, Sairenchi T et al. The relationships of proteinuria, serum creatinine, glomerular filtration rate with cardiovascular disease mortality in Japanese general population. *Kidney Int.* 2006 Feb 22; [Epub ahead of print]
- Johnson RJ, Schreiner GF. Cytokines, growth factors and renal injury: where do we go now? *Kidney Int.* 1997 Nov;52(5):1169-79.
- Julius S, Schork MA. Predictors of hypertension. *Ann N Y Acad Sci.* 1978 Mar 30;304:38-58.
- Kanazawa M, Kohzuki M, Kurosawa H et al. Renoprotective effect of angiotensin-converting enzyme inhibitor combined with alpha1-adrenergic antagonist in spontaneously hypertensive rats with renal ablation. *Hypertens Res.* 2004 Jul;27(7):509-15.
- Kaufman JM, DiMeola HJ, Siegel NJ, Lytton B, Kashgarian M, Hayslett JP. Compensatory adaptation of structure and function following progressive renal ablation. *Kidney Int* 1974; 6: 10-7.
- Kaufman JM, Siegel NJ, Hayslett JP. Functional and hemodynamic adaptation to progressive renal ablation. *Circ Res* 1975; 36: 286-93.
- Kett MM, Denton KM, Boesen EI, Anderson WP. Effects of early carvedilol treatment and withdrawal on the development of hypertension and renal vascular narrowing. *Am J Hypertens.* 2004 Feb;17(2):161-6.
- King AJ, Brenner BM. Endothelium-derived vasoactive factors and the renal vasculature. *Am J Physiol.* 1991 Apr;260(4 Pt 2):R653-62.
- Klag MJ, Whelton PK, Randall BL et al. Blood pressure and end-stage renal disease in

men. *N Engl J Med.* 1996 Jan 4;334(1):13-8

- Kobayashi M, Machida N, Mitsuishi M, Yamane Y. Beta-blocker improves survival, left ventricular function, and myocardial remodeling in hypertensive rats with diastolic heart failure. *Am J Hypertens.* 2004 Dec;17(12 Pt 1):1112-9.
- Kurokawa K. Kidney, salt, and hypertension: how and why. *Kidney Int Suppl.* 1996 Jun;55:S46-51
- Lafayette RA, Mayer G, Park SK, Meyer TW. Angiotensin II receptor blockade limits glomerular injury in rats with reduced renal mass. *J Clin Invest.* 1992 Sep;90(3):766-71
- Lahera V, Salazar J, Salom MG, Romero JC. Deficient production of nitric oxide induces volume-dependent hypertension. *J Hypertens Suppl.* 1992 Dec;10(7):S173-7.
- Levey AS, Beto JA, Coronado BE et al. Controlling the epidemic of cardiovascular disease in chronic renal disease: what do we know? What do we need to learn? Where do we go from here? National Kidney Foundation Task Force on Cardiovascular Disease. *Am J Kidney Dis.* 1998 Nov;32(5):853-906.
- Levey AS, Coresh J, Balk E et al ; National Kidney Foundation. National Kidney Foundation practice guidelines for chronic kidney disease: evaluation, classification, and stratification. *Ann Intern Med.* 2003 Jul 15;139(2):137-47.
- Lewis EJ, Hunsicker LG, Bain RP, Rohde RD. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group. *N Engl J Med.* 1993 Nov 11;329(20):1456-62
- Lewis EJ, Hunsicker LG, Clarke WR et al; Collaborative Study Group. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. *N Engl J Med.* 2001 Sep 20;345(12):851-60.
- Lifton RP., Molecular genetics of human blood pressure variation. *Science.* 1996 May 3;272(5262):676-80.
- Manning RD Jr, Hu L, Williamson TD. Mechanisms involved in the cardiovascular-renal actions of nitric oxide inhibition. *Hypertension.* 1994 Jun;23(6 Pt 2):951-6.
- Maschio G, Alberti D, Locatelli F et al. Angiotensin-converting enzyme inhibitors and kidney protection: the AIPRI trial. The ACE Inhibition in Progressive Renal Insufficiency (AIPRI) Study Group. *J Cardiovasc Pharmacol.* 1999;33 Suppl 1:S16-20; discussion S41-3.
- Mervaala EM, Teravainen TL, Malmberg L et al. Cardiovascular and renal effects of the combination of felodipine and metoprolol during a high-salt and a moderate-salt diet in spontaneously hypertensive rats. *Jpn Circ J.* 1997 May;61(5):421-31

- Meyer TW, Anderson S, Brenner BM. Dietary protein intake and progressive glomerular sclerosis: the role of capillary hypertension and hyperperfusion in the progression of renal disease. *Ann Intern Med* 1983; 832-8.
- Morton JJ, Beattie EC, Speirs A, Gulliver F. Persistent hypertension following inhibition of nitric oxide formation in the young Wistar rat: role of renin and vascular hypertrophy. *J Hypertens*. 1993 Oct;11(10):1083-8.
- Mougnot N, Mediani O, Lechat P. Bisoprolol and hydrochlorothiazide effects on cardiovascular remodeling in spontaneously hypertensive rats. *Pharmacol Res*. 2005 Apr;51(4):359-65.
- Muirhead EE. Renal vasodepressor mechanisms: the medullipin system. *J Hypertens Suppl*. 1993 Dec;11(5):S53-8.
- National Kidney Foundation. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. *Am J Kidney Dis*. 2002 Feb;39(2 Suppl 1):S1-266
- Nguyen T, El Salibi E, Rouleau JL., Reduced periinfarction mortality as a result of long-term therapy with captopril but not hydralazine or propranolol in spontaneously hypertensive rats. *J Cardiovasc Pharmacol*. 1998 Dec;32(6):884-95.
- Novick AC, Gephardt G, Guz B, Steinmuller D, Tubbs RR. Long-term follow-up after partial removal of a solitary kidney. *N Engl J Med* 1991; 325: 1058-62.
- Olson JL, Hostetter TH, Rennke HG, Brenner BM, Venkatachalam MA. Altered glomerular permselectivity and progressive sclerosis following extreme ablation of renal mass. *Kidney Int* 1982; 22: 112-26.
- Page III. On the nature of the pressor action of rennin. *J Exp Med* 1939; 70: 521-542
- Pappenheimer JR. Passage of molecules through capillary walls. *Physiology Rev* 1953; 33: 387-423.
- Patzak A, Kleinmann F, Lai EY, Kupsch E, Skelweit A, Mrowka R. Nitric oxide counteracts angiotensin II induced contraction in efferent arterioles in mice. *Acta Physiol Scand*. 2004 Aug;181(4):439-44.
- Perlini S, Palladini G, Ferrero I et al. Sympathectomy or doxazosin, but not propranolol, blunt myocardial interstitial fibrosis in pressure-overload hypertrophy. *Hypertension*. 2005 Nov;46(5):1213-8. Epub 2005 Oct 10.
- Purkerson ML, Joist JH, Yates J, Valdes A, Morrison A, Klahr S. Inhibition of thromboxane synthesis ameliorates the progressive kidney disease of rats with subtotal renal ablation. *Proc Natl Acad Sci U S A*. 1985 Jan;82(1):193-7.



- Qiu C, Engels K, Baylis C. Endothelin modulates the pressor actions of acute systemic nitric oxide blockade. *J Am Soc Nephrol.* 1995 Nov;6(5):1476-81.
- Rees DD, Palmer RM, Moncada S. Role of endothelium-derived nitric oxide in the regulation of blood pressure. *Proc Natl Acad Sci U S A.* 1989 May;86(9):3375-8.
- Remuzzi G, Bertani T. Is glomerulosclerosis a consequence of altered glomerular permeability to macromolecules? *Kidney Int.* 1990 Sep;38(3):384-94.
- Remuzzi A, Mazerska M, Gephardt GN, Novick AC, Brenner BM, Remuzzi G. Three-dimensional analysis of glomerular morphology in patients with subtotal nephrectomy. *Kidney Int* 1995; 48: 155-62.
- Remuzzi G, Bertani T. Pathophysiology of progressive nephropathies. *N Engl J Med* 1998; 1448-56.
- Remuzzi G, Benigni A, Remuzzi A. Mechanisms of progression and regression of renal lesions of chronic nephropathies and diabetes. *J Clin Invest.* 2006 Feb;116(2):288-96.
- Rettig R, Does the kidney play a role in the aetiology of primary hypertension? Evidence from renal transplantation studies in rats and humans. *J Hum Hypertens.* 1993 Apr;7(2):177-80.
- Ribeiro MO, Antunes E, de Nucci G, Lovisolo SM, Zatz R. Chronic inhibition of nitric oxide synthesis. A new model of arterial hypertension. *Hypertension.* 1992 Sep;20(3):298-303.
- Riser BL, Cortes P, Zhao X, Bernstein J, Dumler F, Narins RG. Intraglomerular pressure and mesangial stretching stimulate extracellular matrix formation in the rat. *J Clin Invest* 1992; 90: 1932-43.
- Ruggenti P, Perna A, Mosconi L et al. Proteinuria predicts end-stage renal failure in non-diabetic chronic nephropathies. The "Gruppo Italiano di Studi Epidemiologici in Nefrologia" (GISEN). *Kidney Int Suppl.* 1997 Dec;63:S54-7.
- Ruggenti P, Perna A, Gherardi G et al. Renoprotective properties of ACE-inhibition in non-diabetic nephropathies with non-nephrotic proteinuria. *Lancet.* 1999 Jul 31;354(9176):359-64.
- Ruggenti P, Perna A, Remuzzi G; GISEN Group Investigators., Retarding progression of chronic renal disease: the neglected issue of residual proteinuria. *Kidney Int.* 2003 Jun;63(6):2254-61.
- Sealey JE, Blumenfeld JD, Bell GM, Pecker MS, Sommers SC, Laragh JH. On the renal basis for essential hypertension: nephron heterogeneity with discordant renin secretion

and sodium excretion causing a hypertensive vasoconstriction-volume relationship.

*J Hypertens. 1988 Oct;6(10):763-77.*

- Shimamura T, Morrison AB. A progressive glomerulosclerosis occurring in partial five sixths nephrectomy. *Am J Pathol 1975; 79: 95-101.*
- Sigmon DH, Carretero OA, Beierwaltes WH. Plasma renin activity and the renal response to nitric oxide synthesis inhibition. *J Am Soc Nephrol. 1992 Dec;3(6):1288-94.*
- Slaiby JM, Ricci MA, Gadowski GR, Hendley ED, Pilcher DB. Expansion of aortic aneurysms is reduced by propranolol in a hypertensive rat model. *J Vasc Surg. 1994 Aug;20(2):178-83.*
- Solomon LR, Mallick NP, Lawler W. Progressive renal failure in a remnant kidney. *Br Med J 1985; 291: 1610-11.*
- United States Renal Data System. 2005. Annual data report atlas. <http://usrds.org/atlas.htm>
- Van de Water A, Xhonneux R, Reneman RS, Janssen PA. Cardiovascular effects of dl-nebivolol and its enantiomers--a comparison with those of atenolol. *Eur J Pharmacol. 1988 Oct 26;156(1):95-103.*
- Van Lommen G, De Bruyn M, Schroven M. Synthesis and pharmacological properties of nebivolol, a new antihypertensive compound. *J Pharm Belg. 1990 Nov-Dec;45(6):355-60.*
- Volhard F, Fahr T. Die Brightsche Nierenkrankheit. Klinik, Pathologie und Atlas. *Springer: Berlin,1914*
- White SL, Cass A, Atkins RC, Chadban SJ. Chronic kidney disease in the general population. *Adv Chronic Kidney Dis. 2005 Jan;12(1):5-13.*
- Wolzt M, Schmetterer L, Ferber W, et al. Effect of nitric oxide synthase inhibition on renal hemodynamics in humans: reversal by L-arginine. *Am J Physiol. 1997 Feb;272(2 Pt 2):F178-82.*
- Wong VY, Laping NJ, Nelson AH et al. Renoprotective effects of carvedilol in hypertensive-stroke prone rats may involve inhibition of TGF beta expression. *Br J Pharmacol. 2001 Nov;134(5):977-84*
- Wood JE, Etheridge C. Hypertension with arteriolar changes in the albino rat following subtotal nephrectomy. *Proc Soc Exp Bio Med 1933; 30: 1039.*
- Xu LP, Shen FM, Shu H, Miao CY, Jiang YY, Su DF. Synergism of atenolol and amlodipine on lowering and stabilizing blood pressure in spontaneously hypertensive rats. *Fundam Clin Pharmacol. 2004 Feb;18(1):33-8.*
- Xue JL, Ma JZ, Louis TA, Collins AJ. Forecast of the number of patients with end-stage

renal disease in the United States to the year 2010. *J Am Soc Nephrol.* 2001 Dec;12(12):2753-8.

- Yi-Lan S, Shen-Jiang H, Li-Hong W, Ying Hu, Jian-Ying Zou. Effect of beta-blockers on cardiac function and calcium handling protein in postinfarction heartfailure rats. *Chest* 2005; 128; 128: 1812-1821
- Yuhara M, Ikeda T, Toya Y, Sakurai J, Gomi T, Ikeda T. Participation of the sympathetic nervous system in hypertension in rats with subtotal renal ablation. *J Hypertens.* 1989 Jun;7(6):443-6
- Zatz R, Dunn BR, Meyer TW, Anderson S, Rennke HG, Brenner BM. Prevention of diabetic glomerulopathy by pharmacological amelioration of glomerular capillary hypertension. *J Clin Invest.* 1986 Jun;77(6):1925-30
- Zatz R, de Nucci G. Effects of acute nitric oxide inhibition on rat glomerular microcirculation. *Am J Physiol.* 1991 Aug;261(2 Pt 2):F360-3.